NASDAQ:LMNXLuminex Stock Price, Forecast & News

Luminex's stock was trading at $27.11 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, LMNX shares have increased by 19.2% and is now trading at $32.32. View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Luminex in the last year. There are currently 1 sell rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Luminex.

Luminex is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for Luminex.

Luminex Co. (NASDAQ:LMNX) issued its quarterly earnings data on Monday, May, 4th. The medical instruments supplier reported $0.01 earnings per share for the quarter, beating analysts' consensus estimates of ($0.01) by $0.02. The medical instruments supplier earned $90.40 million during the quarter, compared to the consensus estimate of $82.30 million. Luminex had a negative return on equity of 1.25% and a negative net margin of 1.81%. Luminex's revenue for the quarter was up 9.7% compared to the same quarter last year. During the same quarter last year, the firm posted $0.07 earnings per share. View Luminex's earnings history.

Luminex declared a quarterly dividend on Tuesday, May 26th. Investors of record on Thursday, June 18th will be given a dividend of $0.09 per share on Thursday, July 9th. This represents a $0.36 dividend on an annualized basis and a yield of 1.11%. The ex-dividend date is Wednesday, June 17th. View Luminex's dividend history.

Luminex issued an update on its second quarter 2020 Pre-Market earnings guidance on Wednesday, July, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $109-110 million, compared to the consensus revenue estimate of $106.25 million.

2 Wall Street analysts have issued 1 year price targets for Luminex's stock. Their forecasts range from $21.00 to $32.00. On average, they expect Luminex's share price to reach $26.50 in the next twelve months. This suggests that the stock has a possible downside of 18.0%. View analysts' price targets for Luminex.

News headlines about LMNX stock have trended somewhat negative on Thursday, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Luminex earned a coverage optimism score of -1.6 on InfoTrie's scale. They also assigned news headlines about the medical instruments supplier a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the near term. View the latest news about Luminex.

Luminex saw a increase in short interest in June. As of June 30th, there was short interest totaling 5,560,000 shares, an increase of 39.0% from the June 15th total of 4,000,000 shares. Based on an average daily trading volume, of 753,600 shares, the days-to-cover ratio is presently 7.4 days. Approximately 13.1% of the company's stock are short sold. View Luminex's Current Options Chain.

Some companies that are related to Luminex include Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Bio-Rad Laboratories (BIO), Waters (WAT), PerkinElmer (PKI), BIO-TECHNE (TECH), Charles River Laboratories Intl. (CRL), Bruker (BRKR), Pacific Biosciences of California (PACB), Fluidigm (FLDM), Harvard Bioscience (HBIO), aTyr Pharma (LIFE) and BG Medicine (BGMD). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Luminex investors own include Baidu (BIDU), NVIDIA (NVDA), Crispr Therapeutics (CRSP), Cisco Systems (CSCO), Inovio Pharmaceuticals (INO), Square (SQ), Verizon Communications (VZ), AbbVie (ABBV), American Express (AXP) and Micron Technology (MU).

Luminex trades on the NASDAQ under the ticker symbol "LMNX."

Luminex's stock is owned by many different retail and institutional investors. Top institutional shareholders include Envestnet Asset Management Inc. (0.23%). Company insiders that own Luminex stock include Charles J Collins, G Walter Loewenbaum II, Nachum Shamir, Nancy Fairchild and Randall Myers. View institutional ownership trends for Luminex.

LMNX stock was acquired by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc.. Company insiders that have bought Luminex stock in the last two years include G Walter Loewenbaum II, and Nachum Shamir. View insider buying and selling activity for Luminex.

Shares of LMNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of LMNX stock can currently be purchased for approximately $32.32.

Luminex has a market capitalization of $1.48 billion and generates $334.64 million in revenue each year. The medical instruments supplier earns $-3,840,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis. Luminex employs 1,247 workers across the globe.

The official website for Luminex is www.luminexcorp.com.

Luminex's mailing address is 12212 TECHNOLOGY BLVD, AUSTIN TX, 78727. The medical instruments supplier can be reached via phone at 512-219-8020 or via email at [email protected]